ImmunoPrecise Antibodies Ltd.
IPA
$0.3918
-$0.0082-2.05%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -74.56% | -31.35% | 1.38% | 48.42% | 40.47% |
| Total Depreciation and Amortization | 10.27% | 6.59% | 7.18% | 13.38% | 47.76% |
| Total Amortization of Deferred Charges | -93.82% | -95.03% | -96.16% | -11.47% | -12.76% |
| Total Other Non-Cash Items | 274.99% | 285.25% | 343.04% | 469.70% | 118.00% |
| Change in Net Operating Assets | 195.49% | 641.94% | 170.12% | 34.57% | 66.20% |
| Cash from Operations | -15.06% | 49.54% | 81.01% | 82.71% | 71.14% |
| Capital Expenditure | -12.19% | 2.56% | 7.78% | 39.10% | 21.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 100.00% | 75.42% | 97.15% | 97.15% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -200.00% | -150.62% | -115.67% | 77.36% | 124.42% |
| Cash from Investing | -16.41% | 22.72% | 21.62% | 84.85% | 81.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 3.46% | 9.72% | -0.15% | -16.79% | -37.56% |
| Issuance of Common Stock | 3,845.92% | 377.55% | 229.61% | -76.84% | -97.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 566.14% | 566.17% | 261.99% | -116.07% | -142.52% |
| Foreign Exchange rate Adjustments | -60.82% | -129.54% | -154.38% | -153.87% | -119.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.70% | 77.74% | 78.35% | 77.18% | 62.96% |
